Tuberous sclerosis complex (TSC), also known as Bourneville disease, is a rare autosomal dominant genetic disorder characterized by the growth of numerous benign tumors throughout the body, including the brain, skin, kidneys, heart, and lungs. It affects approximately 1 in 6,000 to 1 in 10,000 live births and has a prevalence of about 1 in 20,000.
TSC results from mutations in the TSC1 or TSC2 genes, leading to dysregulated mTOR (mammalian target of rapamycin) signaling and abnormal cell growth and proliferation.
¶ TSC1 and TSC2 Genes
| Gene |
Chromosome |
Protein |
Function |
| TSC1 |
9q34 |
Hamartin |
Tumor suppressor |
| TSC2 |
16p13.3 |
Tuberin |
Tumor suppressor |
Mutations in TSC2 account for approximately 70% of cases and typically cause a more severe phenotype. Approximately 15-20% of cases are caused by TSC1 mutations, while 10-15% have no identified mutation.
The TSC1/TSC2 complex normally inhibits mTORC1 (mammalian target of rapamycin complex 1) signaling. Loss-of-function mutations lead to:
- Constitutive mTORC1 activation
- Uncontrolled cell growth and proliferation
- Increased protein synthesis
- Enhanced cell survival
- Occurs in 80-90% of individuals with TSC
- Onset typically in first year of life
- Infantile spasms are common
- Often refractory to antiepileptic drugs
- Consider surgical resection for drug-resistant cases
- Cortical tubers are hallmark brain lesions
- Contribute to epilepsy and cognitive impairment
- Number and location correlate with neurological outcomes
- Present in approximately 50% of cases
- Range from normal intelligence to severe impairment
- Correlates with epilepsy severity and number of cortical tubers
- Affects 25-50% of individuals with TSC
- Associated with temporal lobe tubers
- Early seizure control may reduce risk
¶ Tuberous Sclerosis Associated Neuropsychiatric Disorders (TAND)
- ADHD, anxiety, depression
- Aggression and self-injury
- Sleep disorders
- Hypomelanotic macules (ash-leaf spots) - present in >90%
- Facial angiofibromas (adenoma sebaceum) - present in 75%
- Shagreen patches (connective tissue nevi)
- Periungual fibromas
- Café-au-lait spots
- Angiomyolipomas (benign kidney tumors) - 70-80%
- Renal cysts
- Increased risk of renal cell carcinoma
- May cause hypertension or renal failure
- Cardiac rhabdomyomas - present in 50-70% of infants
- Often regress spontaneously
- Can cause arrhythmias or outflow obstruction
- Lymphangioleiomyomatosis (LAM) - primarily in adult women
- Multifocal micronodular pneumocyte hyperplasia (MMPH)
While TSC is primarily a developmental disorder, the mTOR pathway dysregulation has significant implications for neuronal function and survival:
¶ mTOR Dysregulation and Neuronal Health
Constitutively active mTOR signaling affects:
- Autophagy: Impaired autophagic flux leads to accumulation of damaged proteins and organelles
- Synaptic Plasticity: Altered mTOR-dependent translation affects synaptic function
- Neuronal Survival: Dysregulated cell growth pathways can lead to cellular stress
The mTOR pathway is central to several neurodegenerative conditions:
¶ Epilepsy and Neurodegeneration
Chronic epilepsy in TSC may lead to:
- Progressive cognitive decline
- Neurodegeneration in seizure focus regions
- Increased risk of sudden unexpected death in epilepsy (SUDEP)
Everolimus and sirolimus (rapamycin) are FDA-approved for TSC:
| Indication |
Medication |
Dose |
| Renal angiomyolipoma |
Everolimus |
10 mg daily |
| Subependymal giant cell astrocytoma |
Everolimus |
4.5 mg/m² daily |
| Refractory seizures |
Everolimus |
5-15 ng/mL trough |
- Antiepileptic drugs (AEDs): Vigabatrin is first-line for infantile spasms
- Ketogenic diet may be beneficial
- Surgical resection for drug-resistant cases
- Vagus nerve stimulation (VNS)
- Annual brain MRI for SEGA monitoring
- Renal ultrasound or MRI every 1-3 years
- Cardiac echocardiography in childhood
- Pulmonary function testing in adults
- Neurodevelopmental assessment
- Tsc1 and Tsc2 knockout mice recapitulate key features
- Conditional knockouts allow tissue-specific studies
- mTOR inhibitor treatment reverses some phenotypes
Recent research on Tuberous Sclerosis Complex includes:
- 2024: Title - Description